DENOVOSS De Novo Ossification using human engineered cartilage as cell-free biomaterial
- Coordinator
- Lunds Universitet, Sweden
- Runs
- 1 June 2026 to 31 May 2029
- Status
- Running
- EU funding
- €2.5m
- Total cost
- —
- Partners
- 4 organisations in 3 countries
- Type
- European Innovation Council
- Grant agreement
- 101290394
What the project is doing
In the project's own words, from its summary on CORDIS.
Bone trauma and critical skeletal defects remain a major global health challenge, affecting millions of patients each year and driving multi-billion-euro costs for healthcare systems. Current grafting solutions face persistent limitations in effectiveness and scalability. The unmet need is clear: a potent, safe, consistent, and off-the-shelf product that reliably induces bone formation across clinical contexts. The DENOVOSS consortuim proposes OssiGel, a first-in-class, cell-free regenerative biomaterial derived from engineered human cartilage.
OssiGel is produced from a standardized immortalized mesenchymal stem cell line, decellularized to yield a stable extracellular matrix gel that retains structural proteins and over 2,000 bioactive factors. This unique composition triggers endochondral ossification, the natural developmental pathway of bone formation, thereby orchestrating host-mediated recruitment of progenitor cells and vascularization. Unlike current options, OssiGel combines the potency of living grafts with the safety, reproducibility, and scalability of an acellular, shelf-stable product.
The project will advance OssiGel from TRL4 to TRL6, finalizing a GMP-compliant formulation, validating efficacy in large-animal mandibular models, completing GLP safety studies, and preparing a clinical trial application for first-in-human testing in alveolar ridge augmentation—an accessible, high-volume entry indication in dental and maxillofacial surgery. In parallel, DENOVOSS will establish market validation, reimbursement mapping, IP consolidation, and investor readiness to ensure a credible commercialization pathway.
Ossigel will be addressing urgent patient needs while opening significant commercial opportunities. Capturing a market opportunity estimated at €300–600M annually in safety-priority cohorts with an additional €200–250M in general populations. DENOVOSS will thus deliver a clinically credible, commercially viable, and transformative solution.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Lunds Universitet | Lund | Sweden | Coordinator |
| Universitat Basel | Basel | Switzerland | Participant |
| Nantes Universite | Nantes | France | Participant |
| Dhalion Biotech AB | Lund | Sweden | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI